630 W. Germantown Pike
About Harmony Biosciences
Startup Harmony Biosciences has spun out of Chicago-based Paragon Biosciences.
CEO: Bob Repella
CCO: John Jacobs
10 articles with Harmony Biosciences
Harmony Biosciences To Present Data On Pitolisant In Patients With Narcolepsy At 2019 American Academy Of Neurology Meeting
Highlights include oral presentation on long-term efficacy and safety of pitolisant and key data analyses from pivotal trials
Financing to support the anticipated launch of pitolisant in the U.S. in 2019 and continued company growth
Harmony Biosciences, LLC announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for its investigational product, pitolisant, and has granted Priority Review for this NDA.
Harmony Biosciences Certified As A Great Place To Work In An Independent Survey Of Workplace Cultures
Harmony Biosciences, LLC (Harmony), a private biopharmaceutical company dedicated to developing and commercializing novel treatment options for people living with rare diseases, announced today that the company was certified as a great workplace by independent analysts at Great Place to Work®.
Harmony Biosciences, LLC (Harmony) announced today that the company has received four industry awards for its Know Narcolepsy® disease awareness educational campaign and healthcare professional educational video series
Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy
For type 1 narcolepsy, this sleep-wake instability is linked to low levels of hypocretin, also called orexin. Hypocretin is a neurotransmitter produced in the hypothalamus and has a significant role in wakefulness and regulating rapid eye movement (REM) sleep. But Harmony Biosciences has found an...
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting
Harmony Biosciences, LLC announced that it will present scientific data on its investigational product, pitolisant, which is being studied for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy, at the upcoming 32nd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP".
Expanded Access Program For Pitolisant Is Open And Patients Are Being Enrolled